Arrowhead Earns $25 Million Milestone in Janssen Collaboration

Date : 08/28/2019 @ 2:22PM
Source : Dow Jones News
Stock : Johnson and Johnson (JNJ)
Quote : 131.33  0.0 (0.00%) @ 12:16AM

Arrowhead Earns $25 Million Milestone in Janssen Collaboration

Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Historical Stock Chart

2 Months : From Aug 2019 to Oct 2019

Click Here for more Arrowhead Pharmaceuticals Charts.

By Colin Kellaher


Arrowhead Pharmaceuticals Inc. (ARWR) on Wednesday said it earned a $25 million milestone payment after a unit of Johnson & Johnson (JNJ) began a phase 2b combination study in patients with chronic hepatitis B infection.

The Pasadena, Calif., drug developer said J&J's Janssen Pharmaceuticals unit has begun dosing in the study of different combination regimens, including JNJ-3989, formerly ARO-HBV.

Arrowhead in October agreed to work with Janssen to develop and commercialize ARO-HBV as part of a license and collaboration agreement potentially worth more than $3.7 billion to Arrowhead.


Write to Colin Kellaher at


(END) Dow Jones Newswires

August 28, 2019 09:07 ET (13:07 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest JNJ Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.